Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Assets Average (2021 - 2025)

Historic Assets Average for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $1.2 billion.

  • Krystal Biotech's Assets Average rose 2518.52% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 2518.52%. This contributed to the annual value of $937.1 million for FY2024, which is 3612.62% up from last year.
  • Per Krystal Biotech's latest filing, its Assets Average stood at $1.2 billion for Q3 2025, which was up 2518.52% from $1.1 billion recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Assets Average ranged from a high of $1.2 billion in Q3 2025 and a low of $443.3 million during Q2 2021
  • In the last 5 years, Krystal Biotech's Assets Average had a median value of $679.4 million in 2022 and averaged $753.4 million.
  • Per our database at Business Quant, Krystal Biotech's Assets Average plummeted by 1229.7% in 2023 and then surged by 5332.07% in 2024.
  • Krystal Biotech's Assets Average (Quarter) stood at $538.7 million in 2021, then rose by 5.33% to $567.4 million in 2022, then skyrocketed by 41.76% to $804.4 million in 2023, then grew by 26.7% to $1.0 billion in 2024, then rose by 16.7% to $1.2 billion in 2025.
  • Its Assets Average stands at $1.2 billion for Q3 2025, versus $1.1 billion for Q2 2025 and $1.1 billion for Q1 2025.